Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2000-05-22
2002-10-22
Arthur, Lisa B. (Department: 1655)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023500, C435S006120, C435S069100, C435S252300, C435S320100
Reexamination Certificate
active
06469150
ABSTRACT:
FIELD OF THE INVENTION
The invention relates to nucleotide sequences encoding bradykinin B
1
receptors, recombinant expression vectors containing the genetic information, recombinant host cells capable of expressing the receptors and methods for identifying modulators of bradykinin B
1
receptor activity.
BACKGROUND OF THE INVENTION
The bradykinin (BK) B
1
receptor, first identified in 1977, has been postulated to play a major role in the pathophysiology of chronic pain and inflammation. With some exceptions, most notably in several tissues in dog, the B
1
receptor is not generally present unless its expression is induced by trauma or inflammatory stimuli. Following its induction, evidence suggests that the B
1
receptor upregulates and maintains its own expression via an autocrine feedback loop upon occupation by its native ligands, des-Arg
10
-kallidin (dAKd) or, in the case of rodents, des-Arg
9
-BK (dABk). The autocrine nature of B
1
receptor expression, coupled with the fact that the receptor is not generally expressed in normal, non-traumatized tissues, makes this an attractive target for anti-inflammatory and antinociceptive therapy.
In classical approaches to drug discovery, the activity of compounds are typically first analyzed by direct in vivo administration into test animals, or alternatively, in vitro using animal tissues. These avenues of discovery often lead to the identification of compounds potent in the test animal but of unknown efficacy in humans. In more recent paradigms of drug discovery, screening efforts are typically conducted on cloned human targets but resulting properties of lead candidates are sometimes complicated by lack of efficacy in animal models of choice.
The problem of potent but highly species-specific compounds is being encountered with greater frequency as the use of cloned human receptors in high-throughput drug screening becomes standard procedure. What is needed is an approach to address this problem by (1) looking at in vitro predictors of in vivo efficacy in animals and (2) screening molecules potent at the human receptor for activity at various animal orthologues in order to identify dually active compounds and an animal model useful in early efficacy studies of potential drug candidates.
SUMMARY OF THE INVENTION
In one aspect, the invention relates to a purified DNA molecule encoding a bradykinin B
1
receptor from one of five mammalian species. The invention includes DNA molecules encoding an amino acid sequence chosen from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5 and functional derivatives thereof.
In another aspect, the invention relates to a purified DNA molecule having a nucleotide sequence chosen from SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10 and derivatives thereof.
In a related aspect, the invention relates to an expression vector which comprises a nucleotide encoding a bradykinin B
1
receptor having a sequence chosen from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5 and functional derivatives thereof or a nucleotide having a sequence chosen from SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10 and derivatives thereof.
In yet another aspect, the invention relates to a recombinant cell comprising the expression vector described above and capable of expressing a bradykinin B
1
receptor from the expression vector, as well as a method for producing such a cell. The method comprises transfecting a suitable host cell with the expression vectors described above and maintaining the host cells under conditions in which the bradykinin B
1
gene is expressed.
In a related aspect, the present invention relates to a method of identifying a compound that modulates bradykinin B
1
receptor activity. The method comprises contacting the test compound with a bradykinin B
1
receptor comprising an amino acid sequence chosen from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5 and functional derivatives thereof; and measuring an effect of the compound on the receptor. The bradykinin B
1
receptor may be expressed by a recombinant host cell. The effect to be measured may be a binding effect, for example, the displacement of a peptidic or non-peptidic ligand or a native ligand, such as, des-Arg
10
-kallidin, from the receptor.
In yet another aspect, the invention relates to a method of identifying an animal model for testing compounds with potential efficacy as bradykinin B
1
receptor modulators. The method comprises contacting a test compound with a panel of bradykinin B
1
receptors from several species; measuring an effect of the compound on the receptors; and then selecting an animal model for further study of the compound's efficacy wherein the animal selected represents a species having a bradykinin B
1
receptor that exhibits the desired effect when contacted with the test compound. In this method, the bradykinin B
1
receptors comprise proteins having amino acid sequences chosen from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5 and functional derivatives thereof. Alternatively, the bradykinin B
1
receptors are encoded by nucleotides having sequences chosen from SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10 and derivatives thereof.
In yet another aspect, the invention relates to a method of identifying a compound having dual specificity to modulate bradykinin B
1
receptor activity in two different species comprising contacting the compound with a bradykinin B
1
receptor from a first species; measuring an effect of the compound on said first receptor; contacting the compound with a bradykinin B
1
receptor from a second species; measuring an effect of said compound on said second receptor; and, based on these measurements, determining whether the compound is equipotent for both receptors. In one embodiment, the method enables one to identify a compound having dual specificity to modulate bradykinin B
1
receptor activity in a primate and non-primate.
REFERENCES:
patent: 5712111 (1998-01-01), Linemeyer et al.
patent: 5965367 (1999-10-01), Linemeyer et al.
Judith M. Hall, “Bradykinin Receptors,” Gen. Pharmac., 28 (1) 1-6 (1997).
Jones et al., “Molecular characterisation of cloned bradykinin B1 receptors from rat and human,” European Journal of Pharmacology, 374 423-433 (1999).
Ni et al., “Molecular cloning and expression of rat bradykinin B1 receptor,” Biochimica et Biophysica Acta 1442 177-185 (1998).
Pesquero et al., “Molecular Cloning and Functional Characterization of a Mouse Bradykinin B1 Receptor Gene,” Biomedical and Biophysical Research Communications, 220 219-225 (1996).
Menke et al., “Expression Cloning of a Human B1 Bradykinin Receptor,” J. Biol. Chem., 269, (34) 21583-21586 (1994).
GenBank Accession No. AJ132230, Jones et al., Eur. J. Pharmacol. 374 (3) 423-433 (1999).
GenBank Accession No. X69681, McIntyre, P., Mol. Pharmacol. 44 (2) 346-355 (1993).
MacNeil et al., “Cloning and pharmacological characterization of a rabbit bradykinin B1 receptor,” Biochimica et Biophysica Acta 1264 223-228 (1995).
GenBank Accession No. U47281, Pesquero et al., Biochem. Biophys. Res. Commun. 220 (1) 219-225 (1996).
GenBank Accession No. U44436, Yanagawa et al., “Novel pharmacological selectivity of the cloned murine B1 bradykinin receptor,” unpublished.
GenBank Accession No. L42383, Chai et al., Genomics 31 (1) 51-57 (1996).
GenBank Accession No. U12512, Menke et al., J. Biol. Chem. 269 21583-21586 (1994).
GenBank Accession No. NM_000710, Menke et al., J. Biol. Chem. 269 21583-21586 (1994).
Horlick Robert
Strohl Barbara
Swanson Robert
Webb Maria
Zhao Jiuqiao
Arthur Lisa B.
Goldberg Jeanine
Heslin Rothenberg Farley & & Mesiti P.C.
Pharmacopeia Inc.
LandOfFree
Cloning and characterization of genes encoding bradykinin B1... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cloning and characterization of genes encoding bradykinin B1..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cloning and characterization of genes encoding bradykinin B1... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2992431